672P Real-world study of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy (CASSIOPE): Interim data for patients who had received prior nivolumab
| Autor: | P. Hamberg, P. Gajate Borau, Philippe Barthélémy, Michael Staehler, Giuseppe Procopio, Pierre Bigot, C. Suarez Rodriguez, J.-C. Eymard, Cristina Masini, P. Dutailly, Valerie Perrot |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty biology Cabozantinib business.industry VEGF receptors medicine.medical_treatment Hematology medicine.disease Targeted therapy chemistry.chemical_compound chemistry Renal cell carcinoma Interim Internal medicine medicine biology.protein In patient Nivolumab business |
| Zdroj: | Annals of Oncology. 32:S695-S696 |
| ISSN: | 0923-7534 |
| DOI: | 10.1016/j.annonc.2021.08.068 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|